Navigation Links
Topical Spray Helped Men With Premature Ejaculation
Date:4/6/2009

Study found they could delay orgasm six times longer than before

MONDAY, April 6 (HealthDay News) -- A new spray enabled men with premature ejaculation to delay their orgasm six times longer than before, according to a study that included 300 European men.

The men, with clinically diagnosed premature ejaculation, were randomly selected to receive a placebo spray with no active ingredients (100 men) or the PSD502 spray, which contains 7.5 milligrams of lidocaine and 2.5 mg of prilocaine (200 men).

During the three-month study, the men used either the placebo or the PSD502 spray five minutes before intercourse. The men and their partners then used a stopwatch to record the time from vaginal penetration to ejaculation. The men were instructed to abstain from sexual activity or masturbation for 24 hours before each recorded episode of intercourse.

The men who used the PSD502 spray (treatment group) delayed their orgasm from an average of 0.6 minutes to 3.8 minutes, compared to just over 1 minute for those who used the placebo spray. That means the PSD502 spray helped men last 6.3 times longer than normal, compared to 1.7 times longer than normal for those who used the placebo, the study authors said.

The study found that after three months of treatment:

  • 90 percent of the men in the treatment group were able to delay ejaculation for more than 1 minute following vaginal penetration, compared with 54 percent of those in the placebo group.
  • 74 percent of men in the treatment group were able to last 2 minutes before ejaculation, compared with 22 percent of those in the placebo group.
  • 62 percent of men in the treatment group said their orgasms were "good" or "very good" after three months, compared with 20 percent before the start of the study. For men in the placebo group, the figures were 19 percent at the end of the study and 21 percent before the start of the study.
  • More patients and partners in the treatment group reported improvements in perceived control, personal distress, satisfaction with sexual intercourse, and interpersonal problems.

The most common problems noted in the study were loss of erection and a burning sensation in the vagina.

The study findings were published in the April issue of the journal BJU International.

"Premature ejaculation can be a very distressing condition for men and can cause distress, frustration and make them avoid sexual intimacy," lead researcher Professor W. Wallace Dinsmore, of the Royal Victoria Hospital in Belfast, U.K., said in a news release.

"Our study shows that when the PSD502 spray was applied to the man's penis five minutes before intercourse it improved both sexual performance and sexual satisfaction, which are key factors in treating premature ejaculation."

More information

The U.S. National Library of Medicine has more about premature ejaculation.



-- Robert Preidt



SOURCE: BJU International, news release, April 6, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution
2. Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution
3. Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis
4. Warner Chilcott and NexMed Sign U.S. Collaboration for Topical Alprostadil Treatment for Erectile Dysfunction
5. Topical treatment for age spots, from Harvard Womens Health Watch
6. Summit VetPharm Introduces New Feline Topicals Vectra(TM) for Cats & Kittens and Vectra(TM) for Cats
7. International Federation of Sports Medicine Selects Celadrin(R) Topical Cream as its First and Only Official Joint and Muscle Topical Cream
8. ZARS Pharma Announces Worldwide License Agreement With Galderma Pharma S.A. for Pliaglis(TM), a Topical Local Anesthetic
9. Topical Cream Treats Precancerous Lesions of Vulva
10. ImQuest Presents New Anti-HIV Drug and Topical Microbicide Development Results on Lead Pyrimidinedione Products IQP-0410 and IQP-0528
11. Fougera First-to-Market With Calcipotriene Topical Solution 0.005% (Rx) (Scalp Solution)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... The American Board of Family Medicine's (ABFM) Board of Directors has selected Warren ... James C. Puffer upon his retirement. Dr. Newton will serve in the position of ... end of 2018. Upon assuming the role of President and CEO on January 1, ...
(Date:10/13/2017)... N.Y (PRWEB) , ... October 13, 2017 , ... Lori ... became a member of ElderCounsel, a national organization of elder law and special needs ... changing laws and rules. It also provides a forum to network with elder law ...
(Date:10/13/2017)... NY (PRWEB) , ... October 13, 2017 , ... Ellevate ... people in business to advocate for action towards gender equality at their inaugural Summit ... from around the globe, and reached a social audience of over 3 million. To ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in agile ... a contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise ... use of Agile methodologies in a consistent and high value manner across CMS ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... COPENHAGEN, Denmark , Oct. 2, 2017 The ... tool in the struggle to reverse the tide of prescription ... plan for regulating their medicine intake and stepping down their ... is set to launch in December 2017; the first 100,000 ... access. Learn more at http://www.rebound-solution.com/ ...
(Date:9/25/2017)... , Sept. 25, 2017   Montrium , ... File solutions, today—from the IQPC Trial Master Files ... , NL)—announced that EastHORN Clinical Services has selected ... programs and TMF management. EastHORN, a leading European ... platform to increase transparency to enable greater collaboration ...
(Date:9/19/2017)... 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically ... announced three leadership team developments today:   ... ... Tom ... Veteran medical device executive Josh Stopek , PhD, who ...
Breaking Medicine Technology: